셀트리온 Celltrion
Incheon, South Korea celltrion.com
From their website, Nov 2026
Work here? Claim this listing
- GMP
About
Celltrion develops, manufactures, markets, and sells biopharmaceuticals, biosimilars, small molecules, and novel therapeutics. It operates from Incheon, South Korea, with production facilities in Songdo and a plant in Branchburg, New Jersey, and serves global markets including North America, Europe, Asia, and South America.
Services
Antibody biopharmaceutical R&D
Develops biopharmaceuticals including novel antibody discoveries, biosimilar development, novel therapeutics development, and platform technology development.
Small molecule R&D
Develops new chemical entities, generic products, chemical IMDs, and platform technologies for small molecules.
Candidate antibody screening
Screens candidate antibodies and develops target product profiles.
Cell line development
Develops high-expression cell lines and secures intellectual property rights to source technologies.
Cell line development
Process development
Develops cell culture and purification processes and optimizes processes for commercial manufacturing.
Analytical method development
Develops analytical methods based on A-QbD and studies physicochemical and biological properties, similarity, stability, mechanism of action, and bioanalytical methods.
Formulation development
Carries out preliminary formulation development, formulation characterization studies, delivery device development, and primary container closer system studies.
Pharmacology and toxicology
Conducts pharmacokinetics, pharmacodynamics, and toxicology studies.
ADME, DMPK & toxicology
Biopharmaceutical manufacturing
Manufactures drug substances and drug products at biopharmaceutical production facilities.
CDMO: development & manufacturing
Contract manufacturing
Operates the Branchburg plant as a contract manufacturing site for external clients.
CDMO: development & manufacturing
Distribution
Provides distribution as one of its business areas.
Capabilities
- Assays and studies
- Antibodies · Small molecules · Process development · Analytical development · Toxicology · PK/PD · Bioanalysis · Analytical method development · Physicochemical characterization · Biological characterization · Similarity study · Stability study
2 more
Mechanism of action study · Bioanalytical method development - Scale and capacity
- Songdo campus production capacity of 250,000L · Branchburg plant biopharmaceutical production capacity of 66,000L · Songdo Plant 1: 100,000L · Songdo Plant 2: 90,000L · Songdo Plant 3: 60,000L · Branchburg Plant: 11,000L x 6 lines · PFS filling capacity up to 20.8 million syringes per year
- Therapeutic areas
- Immunology · Oncology · Haematology · Ophthalmology · Endocrinology · Chronic spontaneous urticaria · Allergic asthma · Chronic rhinosinusitis with nasal polyps · Inflammatory bowel disease · Metastatic colorectal cancer · Breast cancer
Instruments and platforms
- Prefilled syringe (PFS) production facility
Modalities and species
- Modalities
- Small molecule · Antibody · ADC · Biosimilar
- Species and models
- Animal cell culture facilities · Cell lines
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Company
- Type
- CRDMO
- Founded
- 2002
Locations
- Based in
- Incheon, South Korea
- Sites
- Incheon, South Korea · Songdo, South Korea · Cheongju, South Korea
- Serves
- North America, Europe, Asia, South America, global
Public records
Similar labs
Work here? Claim this listing